Genbioma Aplicaciones S.L. / proven effectiveness of probiotics for glycemia regulation / the first Probiotic supplement for prediabetics

Metabolic Microbiome Science

About us

About Us

Welcome

Genbioma specializes in research and development services to develop novel, science-based solutions for human health in the field of probiotics and other bioactive compounds.

Our main partners are the dietary supplement and food industries.

GENBIOMA is a commercially oriented Research and Development company committed to scientific innovation in microbiome science. The company’s R&D is based on our proprietary, patented bacterial strains (WO 2021/123355). GENBIOMA is set to revolutionise the market with nutritional supplements based on its proprietary bacterial strains, providing probiotic and postbiotic ingredients with strong scientific evidence. Top 10 Global Nutritional Supplements Trends & Top 10 International Next Wave of Startups of Microbiome Technology (2023).

Genbioma has established alliances with private and public partners, including universities, industry, and world-renowned research centers, to overcome any research, development, and market challenges.
Besides the scientific and industrial founders, the company has a talented team consisting of private investors (Clave Capital), strategic partners from the pharmaceutical sector (CINFA), and experts in animal health and nutrition (Pentabiol S.L.). The company is also supported by a research agreement with the Centre for Nutrition Research at the University of Navarra.

GENBIOMA is a team of health experts dedicated to researching and developing probiotic bacteria for human health food applications. Our team includes scientists from the fields of biology, biochemistry, biotechnology, and food technology.
Our focus on Consumer Health Care and our conviction that probiotics and postbiotics (Microbiome based products) are the future of health benefits have brought us to develop new food products on the market.

Our Company is an innovative biotech technology platform for creating groundbreaking products targeting specific human health needs. Our core expertise lies in finding and developing microorganisms and food applications for industrial and health-related purposes.
Genbioma aims to become an international reference in the nutraceutical and functional food market by investing in R&D to develop probiotics & postbiotics, and new health-focused solutions.
We work closely with our clients to design and customize our products according to their specific requirements.

Partners

Univ. de Navarra

Visitar web

Cinfa

Visitar web

Clave Capital

Visitar web

Pentabiol

Visitar web

UPNA

Visitar web

B2B. Business to Business.

Genbioma is a B2B provider for Dietary Supplements & Food Industry. We are open to different ways to partnership with the goal of covering your specific needs.
If you are interested in becoming one of our partners, please contact us.

info@genbioma.com

Our products

At Genbioma, we create probiotic & postbiotic supplements using objective, measurable criteria that are based on extensive research and trials.
Our strains collection is supported by scientific data, and we use scientifically documented and patented probiotic strains. Additionally, our supplements undergo pre-clinical and clinical trials to ensure their safety and effectiveness. Our probiotic and postbiotic supplements are ready to go, making it easy for you to incorporate them into your daily routine.
Genbioma develops its own probiotic & postbiotic supplements based on objective, measurable criteria, which are the result of research and/or trials on:

Protected strain collection, backed by scientific data.
Scientifically documented and patented probiotic strains.
Pre-clinical and clinical evaluation.
Single-strain food product.
High stability over time so as to guarantee an optimum food supplement.
Probiotics for dietary supplements ready for the market.
Strong IP protection and regulatory support.
Ready-to-go probiotic & postbiotic food supplement.
Safety worldwide open for the international market.

Genbioma aims to be a reference in the Premium Probiotics & Postbiotics market

pA1c(R) & pA1c(R)HI

Probiotic pA1c(R) & Postbiotic pA1c(R)HI are the first Genbioma´s benchmark strain for nutrition brands. The innovation is based on scientific dossiers

- Safety: Whole genome sequencing Grass dossier FDA, QPS list, EFSA/WHO guidelines.

- Industrial manufacturing: Probiotics & Postbiotics Bulk powder and capsules production.

- Metagenomic and metabolomic studies.

- Mechanism of action and impact on microbiota.

- Strong scientific evidence: Preclinical and Human clinical trials: Prestigious Hospitals and Universities Scientific Research agreement.

- Strong IP protection: International patent protected.

- Highly Stable: Postbiotic is more than 2 years stable under any climate condition and food process.

- Natural, allergen-free, non-GMO.

- Vegetable-based ingredients in a registered food facility (applicable standards for GMP).

- Ready for the Consumer Health market.

Reglubetic(R) & Reglubetic(R)HI

Probiotic Reglubetic(R) and Postbiotic Reglubetic(R)HI are a daily oral probiotic supplements.
The solution is a breakthrough in microbiome science based on our exclusive pA1c(R) strain.
Our probiotic contains a unique strain formulation that is exclusively patented and cannot be found in any other probiotic product available in the market.
Ongoing clinical trials and real-life tests in different sites within the EU. If you want to join us, send an email to participa@genbioma.com.

RESEARCH AND
INNOVATION

Genbioma is a research platform for Microbiome based solutions (probiotics and postbiotics).

The research includes the selection, identification, scale-up, and production of our patented strain collection, in vitro and in vivo pre-clinical studies in animal models as well as clinical trials in humans.

Through leading international strategic partners and investment in R&D, Genbioma develops probiotics and postbiotics on an industrial scale and provides a solid scientific base with publications in high-impact scientific journals. The company has a clear orientation towards the international market.

Project and scientific publications

PCPP21: DIABET2PREDICT - Medicina de precisión contra la diabetes tipo 2: Predicción Genética e Intervención Nutricional con Probióticos moduladores de la Microbiota. (1,7M€). Consorcio: GENBIOMA APLICACIONES SL. (Leader), ASOC INSTITUTO DE INVESTIGACION SANITARIA BIOCRUCES BIZKAIA, UNIVERSIDAD DE NAVARRA & PATIA EUROPE, S.L. Proyecto CPP2021-008725 financiado por MCIN/AEI/10.13039/501100011033 y por la Unión Europea “NextGenerationEU”/PRTR”.
NEOTEC 2021: MIGLUCOPROB - Estudio de la microbiota intestinal y de la efectividad de probióticos para la mejorar la glucemia (325K€). CDTI con la colaboración del Ministerio de Ciencia e Innovación y cofinanciado por la Unión Europea – Next Generation EU. Número de expediente SNEO-20211487.
TRANSFERENCIA CONOCIMIENTO GOBIERNO DE NAVARRA (2020) – PREDIABETCARE (416K€). Consorcio Genbioma (líder), UPNA y CIN-UNAV.

Actividad.
5 scientific papers published by international prestigious journals (Q1) since 2022, including Diabetologia. XX communications at international scientific congresses since 2022, including XX selections by the three main global diabetes congresses: American Diabetes Association (ADA), etc

Ayudas a la contratación de personas promotoras y gestoras de proyectos europeos (2023) con número de referencia Código Expediente: 0011-4094-2023-000000 Código BDNS: 680423, subvención por un importe de (€) 15.000.

“Ayudas Programa Europa + Cerca” con número de referencia Código Expediente: 0011-2795-2023-000010, para el cual fue resuelta una ayuda en forma de subvención por un importe de (€) 2.000.

Support Funds

We are very grateful for the awards and support given by:

Support Funds & Awards

Awards

2023:

EmprendeXXI en NAVARRA

Premio Emprende | Alimentaria FoodTech

Scale the Impact

STARTUP OLÉ

2022:

Probiota Pioneers

Premio APTENISA

SELLO PYME INNOVADORA

2021:

EIT FUN&FAN

Support Funds

Esta empresa ha recibido una ayuda cofinanciada al 50% por el Fondo Europeo de Desarrollo Regional a través del Programa Operativo FEDER 2014-2020 de Navarra

get in touch

Location

Contact us

Metabolic Microbiome Science

About us

Welcome

Partners